BERKELEY, Calif. and MAINZ, Germany, May 01, 2023 (GLOBE NEWSWIRE) — Mainz Biomed NV MYNZ (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, today announced its participation in the annual Digestive Disease Week (DDW) conference, taking place May 6-9 this year takes place in Chicago. II. The DDW is the world’s leading gathering of digestive disease professionals from academia and industry, and throughout the conference, members of the Mainz Biomed leadership team will interact with leaders in academia and business, and use the event to host a meeting of the Medical Advisory Board (MAB ) of the company. .

“As a company dedicated to bringing gold-standard molecular diagnostics to market for the treatment and prevention of cancer, including gastroenterological indications, we view DDW as an essential forum to keep up to date with technical innovations and industry trends,” commented Guido Baechler, Chief Executive Officer of Mainzer Biomed. “We are also pleased to host a formal meeting of our MAB during the conference to review corporate programs under development and discuss opportunities to improve the pipeline.”

Mainz Biomed is currently marketing its flagship product ColoAlert^®, a highly effective and easy-to-use colorectal cancer (CRC) detection test in select international territories, and initiated a pivotal clinical trial (ReconAAsense) in the US in December 2022 for a CRC screening test that could integrate the company’s novel portfolio of gene expression (mRNA ) biomarkers. These biomarkers have demonstrated the potential to identify advanced adenomas, a type of curable precancerous polyp commonly attributed to CRC, which are being investigated in European and US studies (ColoFuture/eAArly DETECT). Results from both studies are expected in 2023 and Mainz Biomed anticipates that enrollment in ReconAAsense will begin in mid-2023. The Company’s early-stage pipeline is highlighted by PancAlert, a potential first-in-class…